A Kolkata teacher beats Stage IV ovarian cancer with advanced surgery, genetic testing, and targeted therapy—while inspiring ...

High-grade endometrial carcinomas are a group of diverse and often diagnostically challenging tumors, which include high-grade endometrioid carcinoma (FIGO grade 3), uterine serous carcinoma ...

More than two-thirds of women with ovarian cancer have high-grade serous carcinoma. Up to 90 percent of HGSCs are not detected until they are beyond the ovaries or fallopian tubes, at which point ...

Artificial intelligence (AI) was used to predict response of high-grade extrauterine serous carcinoma (HGSC) to adjuvant platinum chemotherapy. For the first time, researchers used artificial ...

We present an analysis of comprehensive genomic profiling (CGP) of a large series of high grade serous ovarian carcinoma (HGSOC) patients assayed in a nationwide cancer network. Racial disparities in ...

Research published in Clinical Cancer Research describes a new test that is more effective at diagnosing ovarian cancer. The study was carried out by researchers at the University of British Columbia ...

Low-grade serous ovarian cancer (LGSOC) presents differently than the more common high-grade serous carcinoma. It tends to show up in younger people, grows slowly, and has higher survival rates.

Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according ...

Several other studies have characterized the molecular biology and genetics of low-grade serous carcinoma. Compared with high-grade serous carcinomas, low-grade tumors have a much lower frequency of ...

As per DelveInsight’s estimates, among the 7MM, the US captured the highest market of high- and low-grade serous ovarian cancer of nearly USD 1,900 million in 2024, which is expected to increase ...

Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the MAPK signaling pathway, which includes the MEK protein.